Despite that KRAS‐mutated tumors were associated with high PD‐L1 expression and consequently with increased tumor responses toward PD‐(L)1 inhibition [2, 39, 40, 41], no discrepancies between tumor harboring KRAS or other mutations were observed in our cohort. The gene discussed is KRAS; the disease is neoplasm.